SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-005141
Filing Date
2023-01-10
Accepted
2023-01-10 06:05:33
Documents
12
Period of Report
2023-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d416892d8k.htm   iXBRL 8-K 32131
  Complete submission text file 0001193125-23-005141.txt   151678

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amrx-20230110.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20230110_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20230110_pre.xml EX-101.PRE 10810
6 EXTRACTED XBRL INSTANCE DOCUMENT d416892d8k_htm.xml XML 3244
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 23519616
SIC: 2834 Pharmaceutical Preparations